
Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with ...
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, May 30, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T, an in situ personalized combination immunotherapy platform optimized for …